HHS ends COVID-19 EUA declarations for devices and drugs: key dates

Federal health officials just made a major, rules-based shift in how the U.S. handles certain COVID-19 medical products. On June 30, 2026, the Department of Health and Human Services (HHS) announced that Secretary Robert F. Kennedy, Jr. signed determinations terminating the COVID-19 Emergency Use Authorization (EUA) declarations for drugs and biological products and for medical devices.

This is a legal change to the emergency “declaration” authorities—not an instant wipeout of every EUA product on day one. HHS built advance notice periods, and FDA’s EUA framework explains what happens on the termination effective dates.

What HHS ended: the COVID-19 EUA “declarations”

Under FDA’s EUA framework, the HHS EUA Declaration (under section 564 of the Federal Food, Drug, and Cosmetic Act) is distinct from a Public Health Emergency declaration—and it is the foundation that supports FDA’s ability to authorize emergency use when specific criteria are met. In this change, HHS terminated the COVID-19 EUA declarations for two major buckets:

• Drugs and biological products
• Medical devices (including in vitro diagnostics for detection and/or diagnosis of SARS-CoV-2, personal respiratory protective devices, and other medical devices, including alternative products used as medical devices)

The two deadlines: devices first, then drugs/biologics

HHS said the declarations would terminate after advance notice periods—180 days for devices and 12 months for drugs/biologics. The Federal Register notices set the effective dates:

• Devices-related EUA declarations terminate: December 26, 2026
• Drugs/biologics EUA declaration terminates: June 29, 2027

What changes for patients and providers now

For patients, hospitals, clinics, and labs, the practical change is that the legal emergency pathway behind many COVID-19 EUAs will wind down in stages on the scheduled effective dates.

FDA also spells out an operational baseline: on the effective date of each termination, the COVID-19 EUA authorizations for the relevant categories of products that are currently listed on FDA’s webpage will no longer be in effect. That means facilities planning for the transition should focus on which product is authorized under which pathway, and how that status may change as each deadline approaches.

HHS also indicated that, during the transition, it and FDA would continue working with manufacturers on appropriate regulatory pathways—such as traditional approval, clearance, or licensure—for products seeking non-emergency routes.

What to watch next (and what “traditional FDA pathways” means)

Near-term follow-ups are most likely to show up as FDA/EUA-specific implementation steps around the termination dates and as product-by-product transitions from emergency frameworks toward existing FDA review/authorization routes.

• Facility checklists and inventory decisions starting well before Dec. 26, 2026 (devices), then before June 29, 2027 (drugs/biologics).
• Manufacturer documentation and regulatory submissions for products moving into traditional FDA authorization/approval/clearance/licensure pathways.
• FDA updates that reflect what remains authorized and what changes on the effective termination dates.

Bottom line: HHS terminated the COVID-19 EUA declaration authorities in two stages: devices first on Dec. 26, 2026, then drugs/biologics on June 29, 2027. The emergency framework is stepping back over time, so providers and manufacturers should pay close attention to which EUA pathway applies to specific products as the deadlines arrive.

Sources

• HHS press release (June 30, 2026)
• Federal Register (July 2, 2026): Drugs/biologics termination (2026-13374)
• FDA: EUA framework page